Michel Holger, Heißenhuber Frank, Wellmann Sven, Melter Michael, Gerling Stephan
University Children's Hospital Regensburg (KUNO), University of Regensburg, Regensburg, Germany.
Clinic for Cardiology-Electrophysiology, Hospital Barmherzige Brüder, Regensburg, Germany.
Front Pediatr. 2020 Jun 16;8:313. doi: 10.3389/fped.2020.00313. eCollection 2020.
We report on a 12-month-old girl with an ectopic atrial tachycardia successfully treated with the combination of a beta blocking agent and Ivabradine that acts on cardiac pacemaker cells by selectively inhibiting the I channel. Standard therapy had failed to control the tachycardia before. No side effects attributable to Ivabradine were noticed. Due to its mechanism of action Ivabradine is a promising novel agent for the therapy of tachycardia due to increased automaticity. Reports on the use of Ivabradine in young children or infants are rare, but show promising results for congenital junctional ectopic tachycardia. This report adds the second case of ectopic atrial tachycardia in this age group and novel treatment with Ivabradine to the literature.
我们报告了一名12个月大的女孩,患有异位房性心动过速,通过β受体阻滞剂和伊伐布雷定联合治疗成功治愈,伊伐布雷定通过选择性抑制I通道作用于心脏起搏细胞。标准治疗此前未能控制心动过速。未观察到伊伐布雷定引起的副作用。由于其作用机制,伊伐布雷定是一种有前景的新型药物,可用于治疗因自律性增加导致的心动过速。关于伊伐布雷定在幼儿或婴儿中的应用报道很少,但对先天性交界性异位心动过速显示出有前景的结果。本报告为该年龄组异位房性心动过速的第二例病例及伊伐布雷定的新治疗方法增添了文献资料。